The senior research scientist at the Institute for Systems Biology spoke about his presentation on multimodal clinical and lifestyle interventions that improve cognitive outcomes at the 2022 CTAD conference. [WATCH TIME: 4 minutes]
WATCH TIME: 4 minutes
“Just from the get-go, I have to prove that I can call you up and change your blood, and we've proven that in spades. We're changing the way you'd eat, we're changing the way you're exercise, and as you can imagine, there are many, many molecules that change in your blood.”
Alzheimer disease (AD) nonpharmacological treatment includes managing medical conditions and lifestyle modifications such as diet, cognitive training, and exercise in addition to pharmacologic treatment. The Coaching for Cognition in Alzheimer's (COCOA) trial, conducted by Jared Roach, MD, PhD, and colleagues, was designed to assess whether coached multimodal interventions positively changed the trajectory of cognitive decline for individuals with AD or related dementia.1 The trial is a 2-arm randomized controlled trial and collects data from each participant on multiple time points over 2 years.
The investigators hypothesize that multimodal interventions will slow the progression of cognitive decline and that coaching will increase patient compliance for those in the early stages of AD. The COCA trial provides itself as an interventional study that challenges the multimodal multidomain therapies on effectiveness for prevention and treatment on AD. The therapies that use a multimodal approach offer more options for types of interventions that may be more personalized to combat cognitive decline and functional loss.
Roach, a senior research scientist at Institute for Systems Biology, recently sat down with NeurologyLive® at the 2022 Clinical Trials on Alzheimer Disease (CTAD) conference, held November 29 to December 2, in San Francisco, California, to offer more background on his presentation on lifestyle intervention to improving cognitive outcomes and the COCA trial. He also gave his perspective on what may cause analytes to change in the blood and potentially improve the cognitive outcomes of patients.